|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| Revenue: | |||||
| Product sales | |||||
| Development revenue | |||||
| Licensing revenue | |||||
| Total revenue | |||||
| Cost of goods sold | |||||
| Cost of sales (exclusive of items shown separately below) | |||||
| Depreciation and amortization expense included in cost of sales | |||||
| Stock-based compensation expense included in cost of sales | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling & marketing | |||||
| General & administrative | |||||
| Depreciation, depletion and amortization | |||||
| Impairment loss | |||||
| Research & development | |||||
| Depreciation & amortization expenses | |||||
| Stock-based compensation (recovery) expense | |||||
| Restructuring expense | |||||
| Impairment of long-lived assets | |||||
| Goodwill impairment | |||||
| Total operating expenses | |||||
| Loss on extinguishment of debt | |||||
| Loss from operations | |||||
| Interest expense, net | |||||
| Loss on foreign exchange, net | |||||
| Realized gain (loss) on foreign exchange, net | |||||
| Unrealized gain (loss) on foreign exchange, net | |||||
| Gain on deconsolidation of wholly-owned subsidiary | |||||
| Loss on financial instruments, net | |||||
| Gain on sale of notes receivable | |||||
| Other expenses, net | |||||
| Total other income (expense), net | |||||
| Loss before income taxes | |||||
| Income tax recovery | |||||
| Net loss | |||||
| Other comprehensive loss, net of tax | |||||
| Unrealized foreign currency translation loss | |||||
| Fair value gain on changes of own credit risk | |||||
| Total other comprehensive loss | |||||
| Comprehensive loss | |||||
| Basic loss per share | |||||
| Diluted loss per share | |||||
| Weighted average number of shares outstanding - basic | |||||
| Weighted average number of shares outstanding - diluted | |||||
Loading...